Bellevue Sustainable Healthcare (Lux)

Sustainability and health combined in a portfolio: First healthcare fund managed under consideration of ESG criteria

Investments in the 40 most attractive healthcare companies worldwide, regionally diversified and across sub sectors

The sustainability filter includes a "best-in-class" approach and the application of a strict exclusion process

Please select a share class.

Please find a more detailed description of share classes here.

Investment Focus

ISIN-No. LU1819585537

The fund is based on the BB Healthcare Index and invests in healthcare companies worldwide. Alongside the established bottom-up process, companies are selected on the basis of the currently applicable sustainability criteria. We are assisted in this process by the sustainability specialist Sustainalytics.

Indexed performance (as at: 03.12.2021)

NAV: USD 178.06 (02.12.2021)


Fonds (Brutto)
01 Jan 2010 - 01 Jan 2010
An error occurred - no data to display

Rolling performance (02.12.2021)

B-USDBenchmark
02.12.2020 - 02.12.20218.20%13.81%
02.12.2019 - 02.12.202025.18%15.63%
02.12.2018 - 02.12.20198.05%9.08%

Annualized performance (02.12.2021)

B-USDBenchmark
1 year8.20%13.81%
3 years13.49%12.77%
Since Inception p.a.10.87%14.20%

Cumulative performance (02.12.2021)

B-USDBenchmark
1M-5.26%-4.54%
YTD2.25%11.62%
1 year8.20%13.81%
3 years46.33%43.56%
Since Inception42.45%57.69%

Annual performance

B-USDBenchmark
202028.33%13.52%
201923.65%23.24%

Investment Focus

The Bellevue Sustainable Healthcare (Lux) fund is based on the same concept as the Bellevue Healthcare Index. Along with fundamental valuation criteria, sustainability criteria are applied as an additional process step. Thus reference is made to the generally accepted environmental, social and governance (ESG) criteria when assessing companies. Stock-picking thus takes account both of the exclusion criteria and the best-in-class approach to the selection of especially sustainable companies.Show moreShow less

Investment suitability & Risk

SRRI

Low risk

High risk

The aim of the fund is to achieve a good and competitive level of capital growth over the long term. It is especially suitable for investors who wish to focus on sustainability and have an investment horizon of at least five years. The fund exhibits the level of risk that is typical of equity investments.

General Information

Investment ManagerBellevue Asset Management AG
CustodianRBC Investor Services, Luxembourg
Fund AdministratorRBC Investor Services, Luxembourg
AuditorPriceWaterhouseCoopers
Launch date29.06.2018
Year end closing30. Jun
NAV CalculationDaily "Forward Pricing"
Cut of time15:00 CET
Management Fee1.60%
Subscription Fee (max.)5.00%
ISIN numberLU1819585537
Valor number41670698
BloombergBBSHCBU LX
WKNA2JMRF
Total expense ratio (TER)2.23% (30.11.2021)

Legal Information

SFDR categoryArticle 8
Redemption periodDaily

Key data (30.11.2021, base currency USD)

Beta0.73
Volatility16.00
Tracking error10.72
Active share81.45
Correlation0.80
Share ratio0.90
Information ratio0.01
Jensen's alpha4.03
No. of positions40

Top 10 positions

Danaher
Vertex Pharmaceut.
Molina Healthcare
Regeneron Pharma.
Iqvia
Anthem
HCA Holdings
Edwards Lifesciences
Neurocrine Bio.
Halozyme Therapeutics
3.9%
3.8%
3.8%
3.8%
3.6%
3.5%
3.4%
3.4%
3.2%
3.0%

Breakdown by sector

Healthcare
Cash
99.2%
0.8%

Currency

USD
HKD
JPY
DKK
CHF
EUR
GBP
AUD
KRW
NZD
36.1%
20.3%
10.0%
9.7%
7.1%
5.2%
4.6%
2.8%
2.6%
1.5%

Opportunities

  • Investments in the 40 most attractive healthcare stocks worldwide.
  • Proprietary investment process: Half-yearly company evaluation and rebalancing.
  • Underweighting of pharma and US stocks against the relevant healthcare indices.
  • Strong focus on quality mid-caps.
  • Healthcare pioneer since 1993 and today one of the biggest independent investors in the sector in Europe.

Risks

  • Equities are subject to strong price fluctuations and so are also exposed to the risk of price losses.
  • The fund may invest in financial instruments that might have a rather low level of liquidity, which can in turn affect the fund’s liquidity.
  • Investments in foreign currencies are subject to currency risks.
  • Investing in emerging markets entails the additional risk of political and social instability.
  • Increased opportunities through possible derivative transactions go hand in hand with increased risk of loss

After making strong gains in the preceding months, global stock markets took a breather in September and closed the month in negative territory. There were various reasons for the risk-off stance among investors: Reported inflation rates remained high, different parts of the economy experienced supply chain disruptions and there was a property market scare in China triggered by Evergrande, all of which generated some stiff market headwinds. On top of that, the Federal Reserve’s latest policy statement cast a cloud over stock market sentiment too. The Fed signaled that it could start tapering its asset purchases very soon if the economy continues to improve at a satisfactory pace along with the jobs market. Yields on long US government bonds rose in the wake of the central bank's policy-setting meeting. Against this backdrop, the broad MSCI World index retreated 4.2% measured in USD. The MSCI World Healthcare Index was even weaker, shedding 5.2% of its value. The Bellevue Sustainable Healthcare Fund was unable to escape the market downdraft with a price loss of 3.9% (USD / I shares), but it ended the period under review better than the direct benchmark.
 
Looking at individual positions, Baxter was one of the portfolio's advancing stocks in September. The US medtech company announced that it would proceed with its proposed takeover of Hill-Rom, a smaller domestic competitor, which is known for its sophisticated hospital beds. Initial investor skepticism about the deal was ultimately overcome by the realization that the two companies are a good fit from a strategic and technological point of view. Several of the Chinese stocks in the portfolio, which have generally been roiled by turmoil for the past few months, regained some stability and headed north. Examples here are Wuxi Apptec (services), Shandong Weigao (medtech) and China Traditional Chinese Medicine (generics). Going in the other direction, the US company Regeneron was a performance detractor during the month under review. The Biden administration unveiled a plan for cutting drug prices and that fueled some selling in the US biotech firm’s shares.

Bellevue's rule-based investment approach, which has been successfully implemented since 2007 and is also mapped by the Adamant Global Healthcare Index, serves as the basis for the fund. A universe with around 600 stocks? ?is compiled from a global pool with over 4000 listed healthcare stocks based on a preselection. As an additional step compared to the conventional methodology, ESG risks of these 600 investable stocks are identified, which could affect the economic value of a company. Here we rely on the longstanding expertise of our research partner Sustainalytics.

In order to get into the fund portfolio, the companies must meet the following criteria: Appropriate ESG risk profile (best-in-class approach), not involved in severe ESG-relevant controversies and comply with the ten principles of the UN Global Compact. In the case of controversial business areas and practices, revenue thresholds are defined for inclusion. The results of the ESG filter application demonstrate that around 40-50% of the titles meet our strict sustainability requirements. The proven factor analysis is then carried out according to four quantitative and four qualitative parameters. The objective here is to select companies that are inexpensive, have strong growth and have an exceptional competitive position so that they can maintain their leading position also in the future.

The analysis results in a portfolio structure consisting of the 40 most sustainable stocks in the healthcare industry, ten of them per region (Western Europe, North America, Japan / Oceania, emerging markets). The application of the eight factors in the past has typically led to a focus on mid cap stocks and an underweight position in pharma and the North America region relative to the MSCI World Healthcare Index. The rebalancing takes place every six months.

Past performance is not a reliable indicator of future results and can be misleading. As the sub-fund is denominated in a currency that may differ than an investor’s base currency, changes in the rate of exchange may have an adverse effect on prices and incomes. Performance is shown net of fees and expenses for the relevant share class over the reference period. All performance figures reflect the reinvestment of dividends and do not take into account the commissions and costs incurred on the issue and redemption of shares, if any. Individual costs are not taken into account and would have a negative impact on the performance. With an investment amount of EUR 1,000 over an investment period of five years, the investment result in the first year would be reduced by the front-end load of up to EUR 50 (5%) as well as by additional individual custody charges. In subsequent years, the investment result would also be reduced by the individual custody account costs incurred. The reference benchmark of this class is used for performance comparison purposes only (dividend reinvested). No benchmark is directly identical to a sub-fund, thus the performance of a benchmark is not a reliable indicator of future performance of the sub-fund it is compared to. There can be no assurance that a return will be achieved or that a substantial loss of capital will not be incurred. All figures in base currency in %, calculated by the total return / BVI method.Show moreShow less

Aktienbeispiele mit Nachhaltigkeitsbezug 

  • Österreichisches Umweltzeichen

  • Eurosif Transparenzkodex

Rating

  • Portfolio Manager

    Samuel Stursberg

    After receiving his Master of Science in Biochemistry from the University of Basel and a degree in Economics from the University of St. Gallen (lic. oec. HSG), Samuel Stursberg conducted stock analysis at Bank Sarasin among others and was Head Research at Adamant Biomedical Investments AG before joining Bellevue Asset Management as Head Research health Care Funds & Mandates in 2015.
  • Portfolio Manager

    Zahide Donat

    Joined Bellevue in 2015 as Portfolio Manager. Prior to joining Bellevue she spent one year at Credit Suisse AG as banking operations specialist and from 2010 to 2013 as client advisor in the customer center (e-banking Hotline, as of 2012 also Service Line) at Migros Bank AG.
  • Portfolio Manager

    Cyrill Zimmermann

    Dr. Cyrill Zimmerman is Head of Healthcare Funds & Mandates and a member of the Executive Board of Bellevue Asset Management. He founded Adamant Biomedical Investments in 2001 and managed the investment boutique until its acquisition by Bellevue in 2014. Cyrill Zimmerman holds a PhD from the University of Zurich.
1